What is the risk of #thyroidcancer with GLP-1 use
Steady-state blood levels are typically reached by week 4-5 of treatment
CJC-1295 Stimulates (GHS) Growth Hormone Secretion and will keep a steady increase of Growth Hormone and IGF-1, without an increase in prolactin, leading to fat loss, and increased protein synthesis, thereby promoting growth and more
20 mg in female arousal studies Subcutaneous injection: 0.75 mg, 1.25 mg, and 1.75 mg in Phase 2-3 female HSDD trials FDA-approved dose: 1.75 mg subcutaneously as needed, at least 45 minutes before sexual activity Important: These are doses from completed clinical trials
Your individual needs will depend on your weight, height, age, gender, activity level, and weight loss/maintenance goals
Clinical Evidence for Non-Diabetic GLP-1 Use Randomized controlled trials including the STEP program demonstrated GLP-1 agonists produce average weight loss of 10-15% in non-diabetic obese and overweight populations